Pretomanid is indicated for use in a limited and specific population of patients.
- TRADE NAME: PA-824 (TB Alliance)
- INDICATIONS: Part of a combination regimen with bedaquiline and linezolid for the
treatment of adults with pulmonary extensively drug resistant, treatment-intolerant or nonresponsive multidrug-resistant tuberculosis. - CLASS: Antimycobacterial (including antitubercular)
- HALF-LIFE: 17 hours
- FDA APPROVAL DATE: 08/14/2019
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Organic anion transporter-3 substrates, Strong or moderate CYP3A4 inducers - PREGNANCY: There are no studies or available data on pretomanid use in pregnant women to inform any drug-associated risks. Breastfeeding is not recommended during treatment with pretomanid or with combination therapies.
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 07/31/2023
